Biographies

E-mail this page

(All fields required)

Recipient's email address

Please enter a valid email.

Your name

Please enter your name.

Your email address

Please enter a valid email.

Find another Doctor or Researcher

High Res

Daniel T. Starczynowski, PhD

Assistant Professor, UC Department of Pediatrics

Phone: 513-803-5317

Email: daniel.starczynowski@cchmc.org

Show All

Specialties

Visit the Starczynowski Lab.

Biography

Daniel T. Starczynowski, PhD, received his PhD in Molecular Biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an Assistant Professor. Dr. Starczynowski’s laboratory is continuing to investigate the molecular and cellular basis of MDS. The current objective of his research program is to understand the contribution of MDS-associated miRNAs and their targeted genes to the pathogenesis of MDS and progression to AML. He hopes that understanding some of the molecular causes of MDS will enhance our insight into the biology of MDS, and provide novel targeted therapies.

Education and Training

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

Publications

View PubMed Publications

Starczynowski DT, Vercauteren S, Sung S, Brooks-Wilson A, Lam WL, Karsan A. Copy number alterations at polymorphic loci may be acquired somatically in patients with myelodysplastic syndromes. Leuk Res. 2011 Apr;35(4):444-7.

Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol. 2011 Feb;39(2):167-178.e4.

Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan A. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2011 Jan 13;117(2):595-607.

Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol. 2011 Feb;39(2):167-178.

Vercauteren SM, Sung S, Starczynowski DT, Lam WL, Bruyere H, Horsman DE, Tsang P, Leitch H, Karsan A. Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. Am J Clin Pathol. 2010 Jul;134(1):119-26.

Starczynowski DT and A Karsan. Innate immune signaling in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America. 2010 Apr;24(2):343-359.

Starczynowski DT and A Karsan. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010 Mar;9(5):855-6.

Starczynowski DT, F Kuchenbauer, B Argiropoulos, S Sung, R Morin, A Muranyi, D Hogue, R Wells, M Marra, WL Lam, K Humphries, and A Karsan. Identification of miR-145 and miR-146a as microRNAs involved in the pathogenesis of 5q- syndrome. Nature Medicine. 2010Jan;16(1):49-58.

Starczynowski DT, S Vercauteren, S Sung, A Brooks-Wilson, J Spinelli, C Eaves, A Eaves, D Horsman, W Lam, A Karsan. 2008. High-resolution array comparative genomic hybridization of CD34+ cells from patients with low-risk myelodysplastic syndromes predicts overall and leukemia-free survival. Blood. 2010 Oct;112(8): 3412-3424.

Starczynowski DT, Trautmann H, Pott C, Harder L, Arnold N, Africa JA, Leeman JR, Siebert R, Gilmore TD. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene. 2007 Apr 26;26(19):2685-94.

Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 2005 Nov 10;24(49):7355-68.